Symptom control in stem cell transplantation: A multidisciplinary palliative care team approach Part 1: Physical symptoms

Journal of Supportive Oncology

Volumn 8, Issue 3, 2010, Pages 100-116

  Roeland, Eric ^a   Mitchell, William ^a   Elia, Giovanni ^a   Thornberry, Kathryn ^a   Herman, Heather ^a   Cain, Julia ^a   Atayee, Rabia ^a   Bardwell, Wayne ^a   von Gunten, Charles F ^a  

^a UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ATROPINE; BELLADONNA ALKALOID; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DEXAMETHASONE; DICYCLOVERINE; GLYCOPYRRONIUM BROMIDE; HALOPERIDOL; HYOSCYAMINE; LOPERAMIDE; LORAZEPAM; MEGESTROL; METHYLPREDNISOLONE; METHYLSCOPOLAMINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCTREOTIDE; OPIATE; PALIFERMIN; PLACEBO; PREDNISOLONE; PROKINETIC AGENT; SCOPOLAMINE; SEROTONIN ANTAGONIST; TACHYKININ RECEPTOR ANTAGONIST; UNINDEXED DRUG;

ABDOMINAL PAIN; ACCOMMODATION PARALYSIS; ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ANAPHYLACTIC SHOCK; ANGER; ANGIONEUROTIC EDEMA; ANOREXIA; ANTICHOLINERGIC SYNDROME; ANXIETY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BEDTIME DOSAGE; BRONCHOSPASM; CANCER PALLIATIVE THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COMA; CONCENTRATION RESPONSE; CONSTIPATION; CONTINUOUS INFUSION; COPING BEHAVIOR; DELIRIUM; DEMENTIA; DEPRESSION; DIARRHEA; DISTRESS SYNDROME; DOCTOR PATIENT RELATION; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL MOTILITY; GRIEF; HEART EXCITATION; HEART PALPITATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LARYNX EDEMA; MAXIMUM PLASMA CONCENTRATION; MICTURITION DISORDER; MUCOSA INFLAMMATION; MYDRIASIS; NAUSEA; NAUSEA AND VOMITING; NERVE CELL STIMULATION; PAIN; PHOTOPHOBIA; QUALITY OF LIFE; RELAXATION TRAINING; REVIEW; ROLE CHANGE; SIDE EFFECT; SOCIAL ISOLATION; SOMNOLENCE; STEM CELL TRANSPLANTATION; SYMPTOM; TACHYCARDIA; TEAMWORK; THERMOREGULATION; TOTAL PARENTERAL NUTRITION; URINE RETENTION; URTICARIA; XEROSTOMIA; GRAFT VERSUS HOST REACTION; PALLIATIVE THERAPY;

ANOREXIA; ANTIEMETICS; DELIRIUM; DIARRHEA; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MUCOSITIS; NAUSEA; PAIN; PALLIATIVE CARE;

EID: 77954078117     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Williams LA, Wang XS, Cleeland CS, Mobley G, Giralt S. Assessment of symptoms and symptom burden before and after engraftment during allogeneic blood or marrow transplant (BMT). Biol Blood Marrow Transplant 2006;12:135.
2. Little M, Jordens CF, McGrath C, Montgomery K, Lipworth W, Kerridge I. Informed consent and medical ordeal: a qualitative study. Intern Med J 2008;38:624-628. [18808560]
3. Fife BL, Huster GA, Cornetta KG, Kennedy VN, Akard LP, Broun ER. Longitudinal study of adaptation to the stress of bone marrow transplantation. J Clin Oncol 2000;18:1539-1549. [10735903]
4. EPEC-O: Palliative Care Educational Materials. www.cancer.gov/aboutnci/epeco. Accessed April 16, 2010.
5. Jowsey SG, Taylor ML, Schneekloth TD, Clark MM. Psychosocial challenges in transplantation. J Psychiatr Pract 2001;7:404-414. [15990553]
6. Goetzmann L, Klaghofer R, Wagner-Huber R, et al. Psychosocial vulnerability predicts psychosocial outcome after an organ transplant: results of a prospective study with lung, liver, and bone-marrow patients. J Psychosom Res 2007;62:93-100. [17188126]
7. Kelly D, Ross S, Gray B, Smith P. Death, dying and emotional labour: problematic dimensions of the bone marrow transplant nursing role? J Adv Nurs 2000;32:952-960. [11095235]
8. Molassiotis A, Haberman M. Evaluation of burnout and job satisfaction in marrow transplant nurses. Cancer Nurs 1996;19:360-367. [8885484]
9. Larson PJ, Viele CS, Coleman S. Dibble SL, Cebulski C. Comparison of perceived symptoms of patients undergoing bone marrow transplant and the nurses caring for them. Oncol Nurs Forum 1993;20:81-87. [8421652]
10. Lee SJ, Joffe S, Kim HT, et al. Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantation. Blood 2004;104:2194-2200. [15198954]
11. Schulz-Kindermann F, Hennings U, Ramm G, Zander AR, Hasenbring M. The role of biomedical and psychosocial factors for the prediction of pain and distress in patients undergoing highdose therapy and BMT/PBSCT. Bone Marrow Transplant 2002;29:341-351. [11896432]
12. Ho VT, Cutler C. Current and novel therapies in acute GVHD. Best Pract Res Clin Haematol 2008;21:223-237. [18503988]
13. Fung HC, Higman MA, van Besien K. Stem Cell Transplantation. American Society of Hematology Self-Assessment Program. Washington: American Society of Hematology; 2007.
14. Sjogren P, Eriksen J. Opioid analgesics. In: Textbook of Palliative Medicine, Bruera E, Higgenson IJ, Ripamonti C, von Gunten CF, eds. London: Hodder Arnold; 2006:380-389.
15. Niscola P, Romani C, Scaramucci L, et al. Pain syndromes in the setting of haematopoietic stem cell transplantation for haematological malignancies. Bone Marrow Transplant 2008;41:757-764. [18246112]
16. Passik S, Portenoy R. Substance abuse issues in palliative care. In: Principles and Practices of Supportive Oncology. New York: Lippincott- Raven; 1998.
17. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999;17:2971-2994. [10561376]
18. Mannix KA. Palliation of nausea and vomiting. In: Oxford Textbook of Palliative medicine, 2nd ed, Doyle D, Hanks GWC, MacDonald N, eds. Oxford, England: Oxford University Press; 1998:489-497.
19. Navari RM. Antiemetic control: toward a new standard of care for emetogenic chemotherapy. Expert Opin Pharmacother 2009;10:629-644. [19284365]
20. Pisters KMW, Kris MG. Treatment-related nausea and vomiting. In: Principles and Practice of Supportive Oncology. New York: Lippincott- Raven Press; 1998.
21. Ferris FD, Kerr IG, Sone M, Marcuzzi M. Transdermal scopolamine use in the control of narcotic-induced nausea. J Pain Symptom Manage 1991;6:389-393. [1880439]
22. Peggs JF, Shimp LA, Opdycke RA. Antihistamines: the old and the new. Am Fam Physician 1995;52:593-600. [7625332]
23. Clissoid SP, Heel RC. Transdermal hyoscine (scopolamine): a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985;29:189-207. [3886352]
24. Pereira J, Bruera E. Successful management of intractable nausea with ondansetron: a case study. J Palliat Care 1996;12:47-50. [8708852]
25. Ripamonti C, Rodriquez C. Gastrointestinal motility disorders in patients with advanced cancer. In: Topics in Palliative Care, vol 1, Portenoy RK, Bruera E, eds. New York: Oxford University Press; 1997:61-93.
26. Baines MJ. ABC of palliative care: nausea, vomiting, and intestinal obstruction. BMJ 1997;315:1148-1150. [9374893]
27. Twycross RB, Lack SA. Therapeutics in Terminal Cancer. New York: Churchill Livingstone 1990;57-79.
28. Flynn J, Hanif N. Nabilone for the management of intractable nausea and vomiting in terminally staged AIDS. J Palliat Care 1992;8:46-47. [1321904]
29. Khoo D, Hall E, Motson R, Riley J, Denman K, Waxman J. Palliation of malignant intestinal obstruction using octreotide. Eur J Cancer 1994;30A:28-30.
30. Pico JL, Avila-Garavito A, Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 1998;3:446-451. [10388137]
31. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351:2590-2598. [15602019]
32. Peterson DE, Bensadoun RJ, Roila F, ESMO Guidelines Working Group. Management of oral and gastrointestinal mucositis: ESMO clinical recommendations. Ann Oncol 2009:20(suppl 4):174-177. [19454447]
33. Bellm LA, Epstein JB, Rose-Ped AM, Fu R, Martin PJ, Fuchs HJ. Assessment of various topical oral formulations by bone marrow transplant recipients. Oral Oncol 2001;37:42-49. [11120482]
34. Cerchietti LC, Navigante AH, Bonomi MR, et al. Effect of topical morphine for mucositisassociated pain following concomitant chemoradiotherapy for head and neck carcinoma. Cancer 2002;95:2230-2236. [12412178]
35. Berger A, Henderson M, Nadoolman W, et al. Oral capsaicin provides temporary relief for oral mucositis pain secondary to chemotherapy/ radiation therapy. J Pain Symptom Manage 1995;10:243-248. [7629418]
36. Slatkin NE, Rhiner M. Topical ketamine in the treatment of mucositis pain. Pain Med 2003;4:298-303. [12974832]
37. Canbay O, Celebi N, Sahin A, Celiker V, Ozgen S, Aypar U. Ketamine gargle for attenuating postoperative sore throat. Br J Anaesth 2008;100:490-493. [18310675]
38. Ryan AJ, Lin F, Atayee RS. Ketamine mouthwash for mucositis pain. J Palliat Med 2009;12:989-991. [19708855]
39. Innocenti M, Moscatelli G, Lopez S. Efficacy of Gelclair in reducing pain in palliative care patients with oral lesions: preliminary finding from an open pilot study. J Pain Symptom Manage 2002;24:456-457. [12547044]
40. Coda BA, O'Sullivan B, Donaldson G, Bohl S, Chapman CR, Shen DD. Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplant. Pain 1997;72:333-346. [9313274]
41. Pillitteri LC, Clark RE. Comparison of a patient-controlled analgesia system with continuous infusion for administration of diamorphine for mucositis. Bone Marrow Transplant 1998;22:495-498. [9733274]
42. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001;19:2201-2205. [11304772]
43. Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST. The impact of mucositis on alphahemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998;82:2275-2281. [9610710]
44. Van Kraaij MG, Dekker AW, Verdonck LF, et al. Infectious gastro-enteritis: an uncommon cause of diarrhoea in adult allogeneic and autologous stem cell transplant recipients. Bone Marrow Transplant 2000;26:299-303. [10967569]
45. Kelly CP, LaMont T. Clostridium difficile- more difficult than ever. N Engl J Med 2008;359:1932-1940. [18971494]
46. Ippoliti C, Champlin R, Bugazia N, et al. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematological malignancies. J Clin Oncol 1997;15:3350-3354. [9363865]
47. Ripamonti C, Mercadante S. How to use octreotide for malignant bowel obstruction. J Support Oncol 2004;2:357-364. [15357519]
48. Iestra JA, Fibbe WE, Zwinderman AH, van Staveren WA, Kromhout D. Body weight recovery, eating difficulties and compliance with dietary advice in the first year after stem cell transplantation: a prospective study. Bone Marrow Transplant 2002;29:417-424. [11919732]
49. McGarigle CJ. Long-term follow-up of bone marrow transplant patients. Yale J Biol Med 1990;63:503-508. [2293509]
50. Henry L. Immunocompromised patients and nutrition. Prof Nurse 1997;12:655-659. [9248441]
51. Szeluga DJ, Stuart RK, Brookmeyer R, Utermohlen V, Santos GW. Nutritional support of bone marrow transplant recipients: a prospective, randomized clinical trial comparing total parenteral nutrition to an enteral feeding program. Cancer Res 1987;47:3309-3316. [3107808]
52. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974;33:1607- 1609. [4135151]
53. Popiela T, Lucchi R, Giongo F. Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 1989;25:1823-1829. [2483687]
54. Tisdale MJ. Clinical anticachexia treatments. Nutr Clin Pract 2006;21:168-174. [16556927]
55. Berenstein G, Ortiz Z. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2009;Issue 1.
56. Beal JE, Olson R, Lefkowitz L, et al. Longterm efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997;14:7-14. [9223837]
57. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group Study. J Clin Oncol 2002;20:567-573. [11786587]
58. Fearon KC, von Meyenfeldt MF, Moses AG, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomized double blind trial. Gut 2003;52:1479- 1486. [12970142]
59. Moses AW, Slater C, Preston T, Barber MD, Fearon KC. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense supplement enriched with n-3 fatty acids. Br J Cancer 2004;90:996-1002. [14997196]
60. Dewey A, Baughan C, Dean T, Higgins B, Johnson I. Eicosapentaenoic acid (EPA, an omega- 3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev 2007 Jan 24:CD004597. [17253515]
61. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC: American Psychiatric Association; 1994:124-212.
62. Fann JR, Roth-Roemer S, Burington BE, Katon WJ, Syrjala KL. Delirium in patients undergoing hematopoietic stem cell transplantation. Cancer 2002;95:1971-1981. [12404292]
63. Massie MJ, Holland J, Glass E. Delirium in terminally ill cancer patients. Am J Psychiatry 1983;140:1048-1050. [6869591]
64. Minagawa H, Uchitomi Y, Yamawaki S, Ishitari K. Psychiatric morbidity in terminally ill cancer patients: a prospective study. Cancer 1996;78:1131-1137. [8780554]
65. Gagnon P, Allard P, Masse B, DeSerres M. Delirium in terminal cancer: a prospective study using daily screening, early diagnosis, and continuous monitoring. J Pain Symptom Manage 2000;19:412-416. [10908822]
66. Lawlor PG, Gagnon B, Mancini IL, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med 2000;160:786-794. [10737278]
67. Olofsson B, Lundström M, Borssén B, Nyberg L, Gustafson Y. Delirium is associated with poor rehabilitation outcome in elderly patients treated for femoral neck fractures. Scand J Caring Sci 2005;19:119-127. [15877637]
68. Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 2004;291:1753-1762. [15082703]
69. Caraceni A, Nanni O, Maltoni M, et al. Impact of delirium on the short term prognosis of advanced cancer patients. Italian Multicenter Study Group on Palliative Care. Cancer 2000;89:1145-1149. [10964345]
70. Beglinger LJ, Duff K, Van Der Heiden S, Parrott K, Langbehn D, Gingrich R. Incidence of delirium and associated mortality in hematopoietic stem cell transplantation patients. Biol Blood Marrow Transplant 2006;12:928-935. [16920558]
71. Fann JR, Alfano CM, Burington BE, Roth-Roemer S, Katon WJ, Syrjala KL. Clinical presentation of delirium in patients undergoing hematopoietic stem cell transplantation. Cancer 2005;103:810-820. [15643598]
72. Inouye SK, Bogardus ST Jr, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med 1999;340:669-676. [10053175]
73. Marcantonio ER, Flacker JM, Wright RJ, Resnick NM. Reducing delirium after hip fracture: a randomized trial. J Am Geriatr Soc 2001;49:516- 522. [11380742]
74. Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996;153:231-237. [8561204]
75. Lonergan E, Britton AM, Luxenberg J, Wyller T. Antipsychotics for delirium. Cochrane Database Syst Rev 2007 Apr 18:CD005594. [17443602]
76. Schwartz TL, Masand PS. The role of atypical antipsychotics in the treatment of delirium. Psychosomatics 2002;43:171-174. [12075031]